is...trading
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GTOP bouncing
Bid .82
Ask .8399
Still not much volume
cool, give us another one...
CYTR still going...now 1.46
So far, so good in this bloodbath of a market. This is one of only a handful of green tickers on my list today!
Anybody know how to clip that video from that site and post on youtube?
I dont think the Feds will cut before the open. Even if they do, it just reinforces how fkd the economy really is...
I think your right about being down an easy 300 points, regardless...
Heres a link to the website...
http://www.foxbusiness.com/video/index.html
look for the latest video link for "Hip Hop Meets Wallstreet"
Agreed...
Dont you think that from the way the "Sean John" partnership was "announced" that it would make sense to PR this news?
Sounds like they have some franchise deals to be announced soon as well.
I didnt see the broadcast, I am assuming if he mentioned it on the show, its a done deal.
Its a fkn mess out there...
TSX plunges more than 500 points
Last Updated: Monday, January 21, 2008 | 10:44 AM ET
CBC News
The S&P/TSX composite index plummeted more than 500 points in morning trading Monday as it joined a worldwide market sell-off prompted by growing worries of a U.S. recession.
S&P/TSX composite index 3-month chart
The benchmark index was down 511 points at 12,225. That's its lowest level in 14 months.
Every sector was down, led by resource and financial stocks. The TSX metals and mining index dropped 5.9 per cent; the energy group slumped 4.5 per cent; financials fell 3.1 per cent.
Monday's sell-off slashed another $70 billion in market value from the TSX. Since the start of the year, the fall in its total market capitalization is approaching $250 billion.
Continue Article
Weighing on the benchmark Canadian stock index on Monday was a big drop in the price of oil. The price for light sweet crude oil for February delivery was down $1.62 US a barrel at $88.95 US a barrel.
Gold prices also plunged $10 to $871.70 US an ounce.
The TSX endured a four-day sell-off last week that sliced 961 points from the benchmark index. The 6.6 per cent drop in the index last week was its worst weekly performance since 2000.
Asian, European markets down sharply
Asian stock markets set the early tone for Monday. Hong Kong's Hang Seng Index closed at 23,818.86 on Monday, down 1,383.01 points or 5.49 per cent. That was the index's biggest drop since Sept. 11, 2001. Indices in Japan, Australia and China all finished with losses of at least 2.9 per cent.
The selling pressure spread to Europe, where the Financial Times 100-share index was down 3.7 per cent, at 5,684.60.
Frankfurt's Dax index was down more than six per cent, while France's CAC 40 index was down five per cent.
U.S. stock markets are closed Monday for the Martin Luther King Jr. holiday, but market futures for the Dow, Nasdaq and S&P were all sharply lower. The Dow's slide in its last four trading days totalled 679 points.
"People are certainly nervous about a potential recession in the U.S. spilling over to the rest of the world," said David Cohen, director of Asian economic forecasting at Action Economics in Singapore.
"Maybe there's still some wariness about [whether] politicians are able to come up with a compromise and act sufficiently quickly" on a stimulus package, Cohen said. "I think the impact would be marginal anyway."
Canadian investors are looking ahead to Tuesday's Bank of Canada decision on interest rates. Economists see the Canadian central bank cutting its key overnight lending rate by 0.25 of a percentage point to four per cent.
With files from the Associated Press
I would expect they will PR the Sean John connection tomorrow...
This is HUGE in my opinion...
Hello!!! Sean John!!
Also known as; Sean Puffy Combs, Diddy, Puff Daddy, Puff, P. Diddy, Puffy
http://www.seanjohn.com/
Sean John: From Rap To Fashion
By: Boyd Davis
Born in Harlem, New York in 1979, Sean Puffy Combs was still a student at Howard University when he popped into the music business in 1991. He was a rapper/musician first, and then he launched his own music label - Bad Boy Entertainment in 1993. He recorded his own songs and was also launching new talents at the same time.
As the saying goes, music and fashion goes hand-in-hand, and pretty soon, Sean Puffy Combs was seen attending the runway shows in New York, Paris and Milan. In 1998, he launched his fashion label, Sean John, which is his first and middle names.
Geared towards teens and young adults, Sean John is a high-fashion urban street wear line, which is not surprising, because that is the base of Sean Puffy Comb's following in the music business.
In 1999, the clothing line made its debut in Bloomingdales, Macy's, Belk's and Fred Segal.
During the Fall 2001 season, when Sean John was due to debut at New York Fashion Week, Sean Puffy Combs was hitting headline news with a very high profile case in New York. As a show of professionalism as a designer, he went straight from the courtroom to the show.
His much publicized romance with Jennifer Lopez also hit the headlines. And as the alledge bribery case ended, his relationship with J.Lo also ended.
Since then, Sean Combs had dropped his moniker “Puff Daddy” and legally changed it to “P. Diddy.”
The label Sean John had grown to a $450 million business as of 2005 in the U.S.
In 2004, Sean “P. Diddy” Combs was honored by the Council of Fashion Designers of America as Men's Wear Designer of the Year.
In 2005, Combs partnered with Weld Wheels Industries and Weld Racing to introduce the Sean John Wheel Collection - a high-end, quality alternative to mainstream custom wheels.
He was also declared "One of the Most Influential Businessmen in the World" by Time Magazine and CNN.
I shoulda woulda coulda played it much better...
punching myself on this one
In at .30, took most out at .38...holding a few on a lotto gamble for Tuesday...
SO, are you gonna include those options in your 2 to 20K challenge or are you gonna start fresh with 2K on Tuesday?
(Market is closed Monday)
Drink O'clock
Have a great weekend all!
IQW looking sweet today....
holding from yesterday at .30
IQW WooooHoooooo!
IQW Breaking out here...
Fell thru 122
Look out belooooowwwwwwwwwwwwwwwww
maybe we have to wait until they are at least open 30 days...
but i agree, we need some numbers, franchising info... something
Dude, maybe you could reread the PRs before posting...
Our revenues from Video Gaming are also way ahead of schedule as the Tampa unit is approaching $1000/day on a regular basis"
"During the first week of operations, our first HipHopSodaShop in Tampa did an outstanding business with sales leaping from on opening night of $3000 to over $6000/day as the first week concluded."
UGH! Run away!!!
up 52% PM, should be good for a flip today, not sure i would wanna hold this at all, the co is in big trouble if they dont get their financing conditions sorted out by Jan 20th.
was just looking at this...could be good for a quick play today
All out ASTM at .63 (couldnt break and hold the dtop)
Will continue watching for a reentry...
All out of ASTM at .63 (entered at .55)
It couldnt break and hold the double top
JMO
Will look to reenter if it breaks and holds...
Good luck with the new board Lang!
Count me in, I'll play along in the real money 2 to 20K challenge!
Holy Chit! Welcome Back Man!
Yes, you havent missed much, market still sucks.
I did better playing Texas Hold Em for a few days in Vegas last week!
Good to have you back! How did it go?
Somebody just loaded up on ASTM on News...
Aastrom Announces First Patient Treatment With Autologous Stem Cell Therapy for Heart Failure
Tuesday January 15, 1:00 pm ET
Company Milestone Achieved by Initiating Treatments in Heart Failure Patients With Dilated Cardiomyopathy -- a Severe Chronic Disease of the Heart
ANN ARBOR, Mich., Jan. 15, 2008 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM:ASTM - News), a leading regenerative medicine company, today announced that the first patient has been treated with the Company's autologous stem cell therapy for dilated cardiomyopathy (DCM). The milestone marks the first human application of Aastrom's Cardiac Repair Cell (CRC) product to regenerate damaged heart tissue in patients with severely impaired cardiac function.
CRCs are derived from a small sample of a patient's bone marrow that is processed using Aastrom's proprietary Tissue Repair Cell (TRC) technology to generate large numbers of stem and early progenitor cells. Near the end of 2007, the first patient was treated with CRCs in a European compassionate-use case. Cells were administered to the patient via direct injection into the heart muscle. The use of CRCs in patients is ongoing and Aastrom intends to establish treatment for additional DCM patients in several leading European heart centers. It is anticipated that clinical data from the compassionate-use cases will be available during 2008.
``We are very pleased to have successfully achieved this important milestone, and look forward to continuing our development program focused on this promising therapy for the treatment of patients with dilated cardiomyopathy,'' said George Dunbar, President and Chief Executive Officer of Aastrom. ``During 2008, we expect to make significant clinical progress in our cardiac regeneration program and to begin to report clinical results.''
It is expected that the compassionate-use of CRCs will provide useful experience for the development of clinical protocols in future regulatory submissions targeting DCM. In February 2007, Aastrom's proprietary CRCs received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of DCM. In the U.S., Orphan Drug Designation provides a variety of incentives, including seven years of market exclusivity following FDA approval.
In addition to initiating treatment in patients with dilated cardiomyopathy, Aastrom also has development programs using TRC-based products for vascular, bone and neural tissue regeneration applications. The Company recently reported positive interim results from a German Phase I/II trial utilizing Vascular Repair Cells (VRCs) to treat diabetic patients with critical limb ischemia (CLI), the most severe form of peripheral arterial disease. Also reported were positive early data from a German compassionate-use study evaluating the use of Bone Repair Cells (BRCs) to treat patients suffering from osteonecrosis of the femoral head.
ASTM NEWS - Aastrom Announces First Patient Treatment With Autologous Stem Cell Therapy for Heart Failure
Tuesday January 15, 1:00 pm ET
Company Milestone Achieved by Initiating Treatments in Heart Failure Patients With Dilated Cardiomyopathy -- a Severe Chronic Disease of the Heart
ANN ARBOR, Mich., Jan. 15, 2008 (PRIME NEWSWIRE) -- Aastrom Biosciences, Inc. (NasdaqCM:ASTM - News), a leading regenerative medicine company, today announced that the first patient has been treated with the Company's autologous stem cell therapy for dilated cardiomyopathy (DCM). The milestone marks the first human application of Aastrom's Cardiac Repair Cell (CRC) product to regenerate damaged heart tissue in patients with severely impaired cardiac function.
CRCs are derived from a small sample of a patient's bone marrow that is processed using Aastrom's proprietary Tissue Repair Cell (TRC) technology to generate large numbers of stem and early progenitor cells. Near the end of 2007, the first patient was treated with CRCs in a European compassionate-use case. Cells were administered to the patient via direct injection into the heart muscle. The use of CRCs in patients is ongoing and Aastrom intends to establish treatment for additional DCM patients in several leading European heart centers. It is anticipated that clinical data from the compassionate-use cases will be available during 2008.
``We are very pleased to have successfully achieved this important milestone, and look forward to continuing our development program focused on this promising therapy for the treatment of patients with dilated cardiomyopathy,'' said George Dunbar, President and Chief Executive Officer of Aastrom. ``During 2008, we expect to make significant clinical progress in our cardiac regeneration program and to begin to report clinical results.''
It is expected that the compassionate-use of CRCs will provide useful experience for the development of clinical protocols in future regulatory submissions targeting DCM. In February 2007, Aastrom's proprietary CRCs received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of DCM. In the U.S., Orphan Drug Designation provides a variety of incentives, including seven years of market exclusivity following FDA approval.
In addition to initiating treatment in patients with dilated cardiomyopathy, Aastrom also has development programs using TRC-based products for vascular, bone and neural tissue regeneration applications. The Company recently reported positive interim results from a German Phase I/II trial utilizing Vascular Repair Cells (VRCs) to treat diabetic patients with critical limb ischemia (CLI), the most severe form of peripheral arterial disease. Also reported were positive early data from a German compassionate-use study evaluating the use of Bone Repair Cells (BRCs) to treat patients suffering from osteonecrosis of the femoral head.
I wasnt watching, but looks like a fat finger on my chart...
Closed yesterday with a doji, so maybe its up from here.
I'm still on the sidelines for now.
Agreed, waiting it out, could test 52 week low (3.00)
Thats what I was thinking...
Just trying to figure out if this is the bottom or not...
lol Thanks! Thats the plan!
(Good to see your back)
Hey all, will be out for the rest of the week.
Heading to Vegas for a few days...
Have a good one...I know I will.
Its Drink O'Clock...
Have a great weekend all....
Is she falls below 12724...
Look out Belooooooowwwwwwwwwwwwwwwwwwwww...
UGLY!